Wael Nassar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Wael Nassar has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Mostafa A. Mostafa
Department of Internal medicine, Nephrology Section, Faculty of Medicine, October Six University, Cairo, Egypt
3 shared publicationsAbdel-Naser Saad
Department of Internal Medicine, Nephrology Section, Sahel Teaching Hospital, General Organization of Teaching Hospitals and Institutes (GOTHI), Cairo, Egypt
2 shared publications- Dina Sabry
Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Badr University in Cairo, Cairo, Egypt
2 shared publications Esam Kotb
Department of Internal medicine, Nephrology Section, Faculty of Medicine, October Six University, Cairo, Egypt
2 shared publicationsHeba Adel
Department of clinical pathology, stem cells Section, Faculty of medicine, Cairo University, Cairo, Egypt
2 shared publicationsMahmoud Temraz
Department of Internal Medicine, Nephrology Section, Sahel Teaching Hospital, General Organization of Teaching Hospitals and Institutes (GOTHI), Cairo, Egypt
2 shared publications
Latest Publications
- Open Access
- 6 April 2017
- Published by American Association for the Advancement of Science (AAAS) in Biomaterials Research
- Vol. 21 (1) , 3
Erratum to: Umbilical cord mesenchymal stem cells derived extracellular vesicles can safely ameliorate the progression of chronic kidney diseases
[This corrects the article DOI: 10.1186/s40824-016-0068-0.].
- 6 April 2017
- Published by American Association for the Advancement of Science (AAAS) in Biomaterials Research
- Vol. 21 (1) , 3
Open AccessErratum to: Umbilical cord mesenchymal stem cells derived extracellular vesicles can safely ameliorate the progression of chronic kidney diseases
[This corrects the article DOI: 10.1186/s40824-016-0068-0.].
- Open Access
- 28 December 2016
- Published by MedCrave Group Kft. in Journal of Diabetes, Metabolic Disorders & Control
- Vol. 3 (8) , 1-3
Contribution of Endoplasmic Reticulum Stress to the Development and Progression of Diabetes Mellitus
Adaptation is the ability of the cell to sense disturbances, and initiates series of molecular reactions to survive. The main adaptations mechanisms involve atrophy, hypertrophy, hyperplasia and metaplasia. However, throughout these adaptation mechanisms, cells maintain their viability, nevertheless, under certain conditions; adaptive reactions may also produce organ damage. When the cell fails to adapt, it progresses to cell death programs (apoptosis, autophagy and necrosis) resulting in cellular dysfunction, parenchymal scarring and ultimately organ failure ensue. Disruption of these mechanisms from adaptation to cell death may cause unwanted inflammation and disease. ER stress has been contributed to pancreatic β-cell dysfunction and cell death resulting in the development of diabetes. ER stress has also been contributed to pancreatic β-cell dysfunction in more common forms of diabetes associated with obesity. ER stress also downregulates insulin hormone signaling pathways and contributes to the development of diabetes. Several studies have reported increased ER stress markers in pancreatic islets in rodent and in obese humans with type 2 diabetes mellitus. In these review we will discuss how ER stress (as a common early adaptation phase) and expression of unfolded proteins and their role in the development and progression of diabetes mellitus.
- 28 December 2016
- Published by MedCrave Group Kft. in Journal of Diabetes, Metabolic Disorders & Control
- Vol. 3 (8) , 1-3
Open AccessContribution of Endoplasmic Reticulum Stress to the Development and Progression of Diabetes Mellitus
Adaptation is the ability of the cell to sense disturbances, and initiates series of molecular reactions to survive. The main adaptations mechanisms involve atrophy, hypertrophy, hyperplasia and metaplasia. However, throughout these adaptation mechanisms, cells maintain their viability, nevertheless, under certain conditions; adaptive reactions may also produce organ damage. When the cell fails to adapt, it progresses to cell death programs (apoptosis, autophagy and necrosis) resulting in cellular dysfunction, parenchymal scarring and ultimately organ failure ensue. Disruption of these mechanisms from adaptation to cell death may cause unwanted inflammation and disease. ER stress has been contributed to pancreatic β-cell dysfunction and cell death resulting in the development of diabetes. ER stress has also been contributed to pancreatic β-cell dysfunction in more common forms of diabetes associated with obesity. ER stress also downregulates insulin hormone signaling pathways and contributes to the development of diabetes. Several studies have reported increased ER stress markers in pancreatic islets in rodent and in obese humans with type 2 diabetes mellitus. In these review we will discuss how ER stress (as a common early adaptation phase) and expression of unfolded proteins and their role in the development and progression of diabetes mellitus.
- Top Cited PapersOpen Access
- 15 March 2016
- Published by American Association for the Advancement of Science (AAAS) in Biomaterials Research
- Vol. 20 (1) , 1-11
Umbilical cord mesenchymal stem cells derived extracellular vesicles can safely ameliorate the progression of chronic kidney diseases
Background: Bio-products from stem/progenitor cells, such as extracellular vesicles, are likely a new promising approach for reprogramming resident cells in both acute and chronic kidney disease. Forty CKD patients stage III and IV (eGFR 15–60 mg/ml) have been divided into two groups; twenty patients as treatment group “A” and twenty patients as a matching placebo group “B”. Two doses of MSC-derived extracellular vesicles had been administered to patients of group “A”. Blood urea, serum creatinine, urinary albumin creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) have been used to assess kidney functions and TNF-α, TGF-β1 and IL-10 have been used to assess the amelioration of the inflammatory immune activity. Results: Participants in group A exhibited significant improvement of eGFR, serum creatinine level, blood urea and UACR. Patients of the treatment group “A” also exhibited significant increase in plasma levels of TGF-β1, and IL-10 and significant decrease in plasma levels of TNF-α. Participants of the control group B did not show significant improvement in any of the previously mentioned parameters at any time point of the study period. Conclusion: Administration of cell-free cord-blood mesenchymal stem cells derived extracellular vesicles (CF-CB-MSCs-EVs) is safe and can ameliorate the inflammatory immune reaction and improve the overall kidney function in grade III-IV CKD patients.
- 15 March 2016
- Published by American Association for the Advancement of Science (AAAS) in Biomaterials Research
- Vol. 20 (1) , 1-11
Top Cited PapersOpen AccessUmbilical cord mesenchymal stem cells derived extracellular vesicles can safely ameliorate the progression of chronic kidney diseases
Background: Bio-products from stem/progenitor cells, such as extracellular vesicles, are likely a new promising approach for reprogramming resident cells in both acute and chronic kidney disease. Forty CKD patients stage III and IV (eGFR 15–60 mg/ml) have been divided into two groups; twenty patients as treatment group “A” and twenty patients as a matching placebo group “B”. Two doses of MSC-derived extracellular vesicles had been administered to patients of group “A”. Blood urea, serum creatinine, urinary albumin creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) have been used to assess kidney functions and TNF-α, TGF-β1 and IL-10 have been used to assess the amelioration of the inflammatory immune activity. Results: Participants in group A exhibited significant improvement of eGFR, serum creatinine level, blood urea and UACR. Patients of the treatment group “A” also exhibited significant increase in plasma levels of TGF-β1, and IL-10 and significant decrease in plasma levels of TNF-α. Participants of the control group B did not show significant improvement in any of the previously mentioned parameters at any time point of the study period. Conclusion: Administration of cell-free cord-blood mesenchymal stem cells derived extracellular vesicles (CF-CB-MSCs-EVs) is safe and can ameliorate the inflammatory immune reaction and improve the overall kidney function in grade III-IV CKD patients.
- Open Access
- 29 June 2015
- Published by Springer Nature in The Egyptian Journal of Internal Medicine
- Vol. 27 (2) , 48-52
Biopsy of the pancreas: the predictive value and therapeutic impact on autoimmune diabetes
- 29 June 2015
- Published by Springer Nature in The Egyptian Journal of Internal Medicine
- Vol. 27 (2) , 48-52
Open AccessBiopsy of the pancreas: the predictive value and therapeutic impact on autoimmune diabetes
- Open Access
- 1 June 2013
- Published by Springer Nature in The Egyptian Journal of Internal Medicine
- Vol. 25 (2) , 75-79
The link between the fibroblast growth factor-23—klotho—vitamin D3 axis and the renin—angiotensin—aldosterone axis in the development and progression of obesity-related kidney disease
Obesity is established as an important contributor of increased diabetes mellitus, hypertension and cardiovascular disease, all of which can promote chronic kidney disease (CKD). Recently, there is a growing appreciation that even in the absence of these risks, obesity itself significantly increases CKD and accelerates its progression. The aim of this work is to evaluate the link between Renin-Angiotensin-Aldosterone System (RAAS) and FGF23-Klotho-1,25D3 axis and their impact in obese and non-obese CKD patients. In a cross sectional randomized multi centers study, two hundred twenty six CKD patients stage III and IV (eGFR20–60 ml/min/m2) have enrolled in this study as follows: group I; 87 non diabetic CKD patients aged 20–40 years with body mass index (BMI) between 20–25 kgm/m2; group II; 130 non diabetic CKD patients aged 20–40 years with (BMI) >30 kgm/m2 and group III; 89 CKD patients aged >60 years. All patient have been tested for plasma leptinlevels, 1,25-dihydrocholicalciferole (1,25D3), plasmaparathormone (PTH) Serum calcium (Ca), serum phosphorus (PO4), and plasma FGF-23 , plasma renin activity (PRA), plasma angiotensinogen receptor 1 & 2 (AT1 & AT2) and plasma aldosterone (ALD) and pulse wave velocity (PWV). The eGFR was significantly reduced in the obese group II (eGFR = 37.7 ± 13.6) when compared with eGFR of the lean group I (eGFR = 49.3 ± 7.51) were P < 0.001, but not significant when compared with the old age group III (eGFR = 41.0 ± 13.47). The obese group II shows significant increase in the ALD/PRA ratio when compared with the lean group I and old age group III (43.23 ± 14.9) for group II vs 11.29 ± 4.1 for group I, P < 0.001 and 24.91 ± 12.1 for group III, P < 0.05 ). Regarding the FGF23-Klotho-vitD3 axis, its components of the obese group II (FGF23 259.55 ± 138.6 Ru/ml; PTH 77.63 ± X32.4 pg/ml; S.PO 4.74 ± 1.61 mg/dl) were significantly elevated when compared to the lean group I (FGF23 132.81 ± 126.1 Ru/ ml; PTH 59.18 ± 24.7 pg/ml; S.PO4 3.85 ± 0.92 mg/dl); the P values were <0.001, <0.01 and <0.05 respectively , while when compared with the old age group III (FGF23 179.33 ± 237.4 Ru/ml; PTH 70.94 ± 15.26 pg/ml; S.PO4 4.09 ± 0.42 mg/dl), values were of less significance. Plasma insulin levels were significantly high in the obese group II (insulin = 13.73 ± 2.38fg/l) than the lean group I (insulin = 5.59 ± 2.31 fg/l) and P < 0.001 and in group III p. insulin level was 10.7 ± 1.68 (P < 0.05). Obesity per se is an independent risk factor in the development and progression of chronic kidney disease specially in young age patients.
- 1 June 2013
- Published by Springer Nature in The Egyptian Journal of Internal Medicine
- Vol. 25 (2) , 75-79
Open AccessThe link between the fibroblast growth factor-23—klotho—vitamin D3 axis and the renin—angiotensin—aldosterone axis in the development and progression of obesity-related kidney disease
Obesity is established as an important contributor of increased diabetes mellitus, hypertension and cardiovascular disease, all of which can promote chronic kidney disease (CKD). Recently, there is a growing appreciation that even in the absence of these risks, obesity itself significantly increases CKD and accelerates its progression. The aim of this work is to evaluate the link between Renin-Angiotensin-Aldosterone System (RAAS) and FGF23-Klotho-1,25D3 axis and their impact in obese and non-obese CKD patients. In a cross sectional randomized multi centers study, two hundred twenty six CKD patients stage III and IV (eGFR20–60 ml/min/m2) have enrolled in this study as follows: group I; 87 non diabetic CKD patients aged 20–40 years with body mass index (BMI) between 20–25 kgm/m2; group II; 130 non diabetic CKD patients aged 20–40 years with (BMI) >30 kgm/m2 and group III; 89 CKD patients aged >60 years. All patient have been tested for plasma leptinlevels, 1,25-dihydrocholicalciferole (1,25D3), plasmaparathormone (PTH) Serum calcium (Ca), serum phosphorus (PO4), and plasma FGF-23 , plasma renin activity (PRA), plasma angiotensinogen receptor 1 & 2 (AT1 & AT2) and plasma aldosterone (ALD) and pulse wave velocity (PWV). The eGFR was significantly reduced in the obese group II (eGFR = 37.7 ± 13.6) when compared with eGFR of the lean group I (eGFR = 49.3 ± 7.51) were P < 0.001, but not significant when compared with the old age group III (eGFR = 41.0 ± 13.47). The obese group II shows significant increase in the ALD/PRA ratio when compared with the lean group I and old age group III (43.23 ± 14.9) for group II vs 11.29 ± 4.1 for group I, P < 0.001 and 24.91 ± 12.1 for group III, P < 0.05 ). Regarding the FGF23-Klotho-vitD3 axis, its components of the obese group II (FGF23 259.55 ± 138.6 Ru/ml; PTH 77.63 ± X32.4 pg/ml; S.PO 4.74 ± 1.61 mg/dl) were significantly elevated when compared to the lean group I (FGF23 132.81 ± 126.1 Ru/ ml; PTH 59.18 ± 24.7 pg/ml; S.PO4 3.85 ± 0.92 mg/dl); the P values were <0.001, <0.01 and <0.05 respectively , while when compared with the old age group III (FGF23 179.33 ± 237.4 Ru/ml; PTH 70.94 ± 15.26 pg/ml; S.PO4 4.09 ± 0.42 mg/dl), values were of less significance. Plasma insulin levels were significantly high in the obese group II (insulin = 13.73 ± 2.38fg/l) than the lean group I (insulin = 5.59 ± 2.31 fg/l) and P < 0.001 and in group III p. insulin level was 10.7 ± 1.68 (P < 0.05). Obesity per se is an independent risk factor in the development and progression of chronic kidney disease specially in young age patients.